CONEXUS PHARMA
Turnover and EBIT margin are not published. The abbreviated or micro format does not require them.
Balance sheet
balance sheet total €15,718 on 31-12-2016in euro
in euro
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2016 | 2015 | 2014 |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
15,718 | 25,653 | 52,797 | |
20 |
684 | 1,026 | 1,368 | |
21/28 |
- | 14,976 | 19,968 | |
21 |
- | 13,950 | 18,600 | |
29/58 |
15,034 | 10,677 | 32,829 | |
40/41 |
- | 1,380 | 1,197 | |
41 |
- | 1,380 | 1,197 | |
54/58 |
15,034 | 9,297 | 31,631 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
15,718 | 25,653 | 52,797 | |
10/15 |
14,759 | 16,599 | 52,797 | |
10/11 |
61,500 | 61,500 | 61,500 | |
100 |
61,500 | 61,500 | 61,500 | |
14 |
-46,741 | -44,901 | -8,703 | |
17/49 |
958 | 9,054 | - | |
42/48 |
958 | 9,054 | - | |
44 |
- | 4,023 | - | |
440/4 |
- | 4,023 | - | |
45 |
665 | 5,032 | - | |
450/3 |
665 | 5,032 | - | |
47/48 |
293 | - | - | |
| Income statement | ||||
9900 |
-8,139 | -30,691 | -2,889 | |
630 |
342 | 4,992 | 4,992 | |
640/8 |
473 | 472 | 835 | |
9901 |
-8,953 | -36,156 | -8,716 | |
75/76B |
7,322 | 41 | 174 | |
75 |
1 | 41 | 174 | |
76B |
7,321 | - | - | |
65/66B |
208 | 84 | 161 | |
65 |
208 | 84 | 161 | |
9903 |
-1,839 | -36,198 | -8,703 | |
9904 |
-1,839 | -36,198 | -8,703 | |
9905 |
-1,839 | -36,198 | -8,703 | |
| Appropriation of the result | ||||
9906 |
-46,741 | -44,901 | -8,703 | |
| Document | ||||
Source: Annual accounts 2016 (PDF), filed on 01-08-2017.
Filings
each dot is a set of accounts, on the day it reached the National Bank2016 annual accounts filed 1 day after the deadline. Filed on 1 August 2017, deadline 31 July 2017 (7 months after the close on 31 December 2016, Companies Code art. 3:10). Source: NBB, 2017-38700323.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2016 | 2015 | 2014 |
|---|---|---|---|---|
| -8,611 | -31,164 | -3,724 | ||
| -1,497 | -31,206 | -3,711 | ||
| -13,950 | 0 | 23,250 | ||
| 5,737 | -22,335 | - | ||
| 14,075 | 1,623 | - | ||
| 93.9% | 64.7% | 100.0% | ||
| 15.69 | 1.18 | - | ||
| 0.06 | 0.55 | - | ||
| -12.5% | -218.1% | -16.5% | ||
| -11.7% | -141.1% | -16.5% |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Insights on CONEXUS PHARMA
The operating result for 2016 is a loss of €8,953, smaller than the loss of €36,156 in 2015.
Debt's share of the balance-sheet total falls from 35.3% to 6.1%. Equity and debt are lower.